Our look is new. Our purpose is the same. Learn more about our brand evolution.
GlaxoSmithKline PLC (GSK) announces partnership to develop therapeutics to treat FSHD.  The goal of the new agreement is to develop a small-molecule-based medicine to potentially reverse FSHD
Year-End Challenge to Fund the Treatment for FSHD! A group of long-time supporters have come forward to challenge the Society’s members and friends to make gifts to Fund the Treatment […]
Canadian Foundation Launched! Great news for Canadians who wish to support FSHD research! Canadians can now donate funds directly towards FSHD research — and receive a tax deduction. The FSHD […]
Exciting news to report! A watershed paper was published online in Nature Genetics identifying the mutation in a gene causing the non-chromosome-4-linked FSHD disease called FSHD1B or FSHD2
San Francisco, CA / November 08, 2012 Just two decades ago, the scientific world largely ignored a mysterious disease that causes muscles to weaken throughout the body. Called fascioscapulohumeral muscular […]
